Soy Isoflavones: Evidence, Amounts, Forms, and Label Guide

Soybeans contain several isoflavones. Genistein, daidzein, and glycitein are the main compounds discussed on supplement labels and in soy research. They are called phytoestrogens because their structures are related to estradiol and they can interact with estrogen receptors. They are not human estrogen and are not the same treatment as menopausal hormone therapy. ^{1, 3}

Whole soy foods, soy protein, soy lecithin, and concentrated isoflavone extracts are also different products. They can contain different amounts and profiles of isoflavones, as well as different proteins, fiber, and other food components. Evidence from one of these categories should not be transferred automatically to another. ^{1, 4}

There is no established Daily Value for soy isoflavones

A Supplement Facts panel may state an amount in milligrams, but soy isoflavones do not have an FDA Daily Value. A missing percent Daily Value is therefore not evidence that the amount is trivial, proven, or suitable for a particular person. ⁹

Even recent reviews of randomized trials do not produce one uniform answer. A 2024 meta-analysis of five trials found no significant improvement in overall menopausal symptoms or quality of life and reported a high risk of conflict of interest in the included studies. A 2025 meta-analysis found a small improvement in combined symptom scores but no significant effect on hot flashes, excessive sweating, insomnia, or the combined vasomotor category. Product composition, reporting basis, population, duration, and outcome choice all matter. ^{6, 10}

Soy isoflavones can occur as free aglycones, simple glucosides, and other conjugated forms. Genistein, daidzein, and glycitein are the aglycone names; genistin, daidzin, and glycitin are their simple glucosides. The attached sugar contributes mass, so a glycoside-based total and an aglycone-equivalent total can give different numbers for related material. ^{4, 5}

The NIH soy-research workshop recommended clear product characterization because an unqualified total can be interpreted in different ways. Aglycone wording can improve clarity, but it does not prove superior symptom relief or make every study directly comparable. ⁴

As one current regulatory example, Health Canada’s 2026 monograph requires quantified total aglycone isoflavone equivalents for its specified soy-extract and isolate claims. That Canadian labeling framework is useful context, but it is not a universal rule for every market or a prediction of how much an individual will absorb. ¹¹

The largest number on the row is not always the active comparison number. Read the ingredient name, source mass, stated yield, individual-compound breakdown, serving size, and directions as one disclosure. Then keep each number attached to what it actually measures.

Phrases such as high potency, clinically studied, fermented, or menopause strength do not resolve a missing isoflavone amount or an unnamed reporting basis. A trademark can identify a supplied material, but the finished label still needs enough disclosure for a meaningful comparison.

Soy isoflavones may appear in a standalone capsule, a menopause blend, and a broader women’s-health formula. The same stack may also contain Red Clover, which has a different isoflavone profile, or Black Cohosh, which should not be counted as an isoflavone source merely because it appears in the same product category.

Calcium and Vitamin D3 may appear beside soy isoflavones in bone-support formulas. Each has a different amount, evidence base, safety context, and label unit. A shared marketing goal does not turn them into one combined dose.

For a cross-ingredient view of vasomotor claims, see What Supplements Actually Help Hot Flashes?

EFSA reported that supplements marketed to peri- and postmenopausal women commonly provided 35 to 150 mg of isoflavones per day. That range describes products and studied exposure; it is not a recommendation for every person. EFSA could not derive one health-based guidance value across the different preparations. ³

A separate 2026 Health Canada monograph uses 30 to 125 mg of total aglycone isoflavone equivalents per day for specified menopause-related soy-extract claims. This is a Canadian product-licensing and labeling framework, not a universal personal dose recommendation. ¹¹

Trial doses are also difficult to compare when one paper reports total glycosides, another reports aglycone equivalents, and another uses soy protein with an isoflavone profile. The product, basis, population, duration, and outcome need to match before a retail label can be described as equivalent to a study. ⁴

Soy can cause allergic reactions, and U.S. labels must identify soy as a major food allergen. Reported short-term side effects can include bloating, constipation, diarrhea, and nausea. NCCIH reports that concentrated soy extracts have been used safely for up to six months, while long-term supplement safety is less certain. ¹

EFSA’s review did not support an increased breast-cancer risk in its observational data or effects on mammographic density and the Ki-67 proliferation marker in intervention studies. It found no effect on endometrial thickness or thyroid hormone levels within the studied postmenopausal exposures and durations. EFSA still could not set one health-based guidance value, and non-malignant uterine changes were reported after 60 months in one study. These findings should not be converted into an unlimited-safety claim. ³

Evidence supports the safety of eating soy foods for women with or at risk for breast cancer, but NCCIH says the safety of concentrated soy-isoflavone supplements in these groups remains uncertain. A current or previous estrogen-sensitive cancer, active cancer treatment, or use of endocrine therapy needs clinician-specific review rather than a conclusion from the front label. ¹²

Soy foods and soy protein have been reported to interfere with levothyroxine absorption in some use contexts, but the evidence is limited and should not automatically be transferred to every isolated soy-isoflavone capsule. A 2023 review noted that the available prospective randomized study did not find impaired levothyroxine absorption when soy isoflavones were taken concomitantly. People using thyroid hormone should still follow consistent medication instructions and the timing plan provided by their prescriber or pharmacist. ^{8, 13}

NCCIH advises that amounts greater than those commonly found in food may be unsafe during pregnancy, and safety above food amounts while breastfeeding is not well known. A menopause-oriented label does not establish suitability during pregnancy or lactation. ¹